Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 for Pain in mCRPC
NCT02278055Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- Feb 2022
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Percentage of Participants With 30% Decline in the Brief Pain Inventory (BPI) Worst Pain Item at 8 weeks. Started Oct 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02278055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278055.